Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Key Terms

rnai medical

RNAi, short for RNA interference, is a natural cellular process that acts like a mute button for specific genes by using small RNA molecules to stop a target gene from producing its protein. For investors, RNAi matters because it is the underlying mechanism behind a class of precision medicines that can silence disease-causing genes, offering high potential returns but also scientific, regulatory and manufacturing risks unique to novel drug platforms.

ai agents technical

AI agents are computer programs designed to perform tasks or make decisions automatically, often by learning from data and adapting to new information. They act like virtual assistants or robots that can handle complex activities without human intervention, which can help businesses and individuals save time and improve efficiency. For investors, AI agents matter because they can enhance decision-making and automate processes that influence markets and financial outcomes.

healthcare intelligence technical

Information and analysis about medical markets, technologies, patient trends, regulatory changes and provider behavior that helps anticipate how healthcare businesses will perform. Like a GPS or weather forecast for health industry decisions, it turns raw data into clear signals about growth opportunities, risks and competitive positioning, helping investors judge which companies may gain market share, face regulatory headwinds, or see changes in revenue and costs.

real-time intelligence technical

Real-time intelligence is continuous collection and analysis of live market data, news, and signals to produce immediate, actionable insights for decision-making. Like a live traffic report for investments, it highlights sudden price moves, breaking news, or changing risk conditions so investors can react faster, manage exposure, and seize short-term opportunities that delayed information might miss.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences

Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- Komodo Health^®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo’s analytics AI platform, across key enterprise functions at Alnylam.

Built on the Healthcare Map^®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyond fragmented analytics and static reporting toward real-time, transparent, and reproducible healthcare intelligence. Launched in August 2025, Alnylam was an early adopter of the platform, with the collaboration initially focused on building custom AI agents for Alnylam’s commercial business function.

The expanded partnership will enable Alnylam to deploy Marmot across its customer-facing organization and leverage its capabilities more broadly across the enterprise, creating a unified foundation for data-driven decision-making at scale.

“Alnylam’s ability to create meaningful impact is built on breakthrough science, strong execution, and an unwavering commitment to patients,” said Tolga Tanguler, Chief Commercial Officer at Alnylam. “This new capability strengthens our ability to connect insight into action, helping us scale more effectively, accelerate decision-making, and continue delivering sustainable growth while maintaining our focus on patients.”

Since initially deploying Marmot, Alnylam and Komodo have built and deployed custom AI agents across critical workflows. Alnylam has integrated a wide range of enterprise datasets into the platform, transforming how teams access and act on insights by eliminating reliance on fragmented dashboards, reducing reporting cycles from months to hours, and enabling teams to generate insights that were previously out of reach. Marmot will continue to support Alnylam as the company works toward a range of operational and patient impact objectives.

Advancing the Next Generation of Enterprise Healthcare AI

The expanded partnership reflects a broader shift occurring across healthcare and Life Sciences as organizations move beyond AI experimentation and begin adopting new operating models built around real-time intelligence. As the limitations of disconnected dashboards, static reporting, and siloed analytics become increasingly apparent, the focus is turning toward enterprise-wide systems that can continuously generate, distribute, and operationalize trusted, verifiable insights across teams.

“We’re moving from a world where every team operates from its own reports and analyses to one where an entire enterprise sees the same reality in real time and can act on it,” said Arif Nathoo, MD, CEO and Co-Founder of Komodo Health. “Marmot is not only a productivity improvement; it’s a new operating model. Alnylam is demonstrating what becomes possible when AI evolves into an intelligence layer that powers how an organization runs.”

New Marmot Capabilities Support Enterprise-Wide Adoption

To support this next phase of enterprise AI adoption, Komodo also released several new Marmot capabilities designed to make healthcare intelligence accessible to every user, from business leaders and consultants to analysts and data scientists. These latest capabilities deliver unprecedented visibility, knowledge, and control over healthcare data, ensuring every analysis is reproducible, verifiable, and executed with unmatched speed and confidence.

“The organizations seeing the greatest value from AI aren’t simply generating insights faster; they’re embedding trusted intelligence directly into the workflows that drive critical decisions,” said Amit Sangani, Chief Technology Officer at Komodo. “These new capabilities are designed to help organizations move beyond experimentation and build AI into the core processes that drive the enterprise, without sacrificing the scientific rigor healthcare demands.”

To learn more, register for today’s live launch event at 1 PM ET/ 10 AM PT here or visit our Product Updates page.

About Komodo Health

Komodo Health^® is building the trusted AI-powered intelligence layer for healthcare and Life Sciences. Powered by the Healthcare Map^®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys, Komodo’s healthcare-native AI analytics platform, Marmot™, equips organizations with the intelligence needed to answer critical healthcare questions across clinical development, market access, commercialization, and real-world evidence. Designed for transparency, auditability, and reproducibility, Marmot enables teams to move from question to decision with greater speed and confidence. For more information, visit komodohealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260625007024/en/

Media Contact
Tate LaCasse
PR Manager
media@komodohealth.com

Source: Komodo Health